RxDoctor Payments Data

Judit Kuhn, MD

Critical Care Medicine · Raleigh, NCNPI 1962721985

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.5% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by GSK at 29.0% of the total. Reporting peaked in 2020 at $282 and has fallen 73.4% since, to $75 in 2024.

$991in general payments, 2019–2025

Across 72 payments — averaging $13.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$287
  • Boehringer Ingelheim$238
  • AstraZeneca$175
  • Sanofi$62
  • Mylan Specialty L.p.$52
  • Masimo Corporation$43
  • plus $135 from 6 others

What the payments were for

  • Food & beverage$96697%
  • Education$253%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$991 in reported general payments places this provider in the 70th percentile of 190 critical care medicine providers in North Carolina.

See all critical care medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$41,480
Medicare patients
203
Services billed
358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter168$122,271
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr58$35,254
Breo ElliptaFluticasone/Vilanterol38$16,349
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$13,562
Pirfenidone13$9,726
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$9,190
SymbicortBudesonide/Formoterol Fumarate31$6,684
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$2,927
Albuterol Sulfate HfaAlbuterol Sulfate82$1,636
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$677
MethotrexateMethotrexate Sodium18$345
Azithromycin32$231
Omeprazole15$198
Prednisone46$160
Montelukast Sodium15$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$287$173,875264 claims
AstraZenecaBreztri Aerosphere, Symbicort$175$15,87544 claims
Boehringer IngelheimStiolto Respimat$238$13,56216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 190 critical care medicine providers in North Carolina.

Other critical care medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →